About the study
This Phase 2 study tested different doses of BI 1839100, an investigational oral medicine, against placebo for 12 weeks in people with idiopathic pulmonary fibrosis (IPF) or progressive pulmonary fibrosis (PPF) who had a troublesome chronic cough. Cough was measured over 24 hours with a portable device, along with questionnaires and breathing tests.
Who took part
The study enrolled people who:
- Had IPF (age 40 or older) or progressive pulmonary fibrosis (age 18 or older)
- Had a chronic cough for more than 8 weeks
Status at Veritas
This study was ended early by the sponsor and is no longer enrolling. It is listed here as part of Veritas Clinical Research's track record as a research site.
Learn more
The full study record, including all eligibility criteria and outcome measures, is on ClinicalTrials.gov (NCT06360094).